Published on Jan 31, 2014
Dr. David Samadi, member of the Fox News Medical "A-Team" and Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York, discusses his thoughts on a new study in the British Medical Journal that states that there is no benefit to prostate cancer screening.
Dr. Samadi feels that there is a definite benefit to screening, and that the data used for this study is faulty due to the lack of standardized PSA testing during its first six years. He also places emphasis on doctors looking at several factors that help determine whether a patient is at risk of prostate cancer. This includes not only PSA level, but watching PSA velocity (the rate at which PSA levels rise over time), and paying attention to a patient's family history, as there is a strong genetic link to prostate cancer developing.
When caught early, prostate cancer has a very high cure rate. However, if it is not treated and it spreads to the bone then treatment becomes incredibly difficult. This is why Dr. Samadi feels that carefully monitoring each patient on an individual basis and paying attention to the risk factors involved in each case, along with PSA screening, is an incredibly beneficial process.
To view more health-related videos by Dr. Samadi on YouTube please follow this link:
You can also visit Dr. Samadi's website at:
To sign up for Dr. Samadi's monthly newsletter please follow this link:
To read Dr. Samadi's blogs please follow these links:
Standard YouTube License